CRDF Stock Analysis: Buy, Sell, or Hold?
CRDF - Cardiff Oncology, Inc. Common Stock
$1.61
-0.01 (-0.62%)
▼
5d:
-6.94%
30d:
-14.81%
90d:
-43.9%
HOLD
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
CRDF is down 13.9% this week, but smart money is accumulating calls. Top strike: $2.5 2026-05-15 with 7,799 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRDF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CRDF shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $1.61, which is considered oversold relative to its 30-day fair value range of $1.67 to $1.96.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.55, while resistance sits at $1.87.
Market Sentiment: CRDF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.75 (+381.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.55, while resistance sits at $1.87.
Market Sentiment: CRDF has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.75 (+381.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.67 -
$1.96
Company Quality Score
54/100
(HOLD)
Options IV Signal
27th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 27th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 381.4% below Wall St target ($7.75)
- CAUTION: Recommendation downgraded due to -6.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$1.67 -
$1.96
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.41
(25.3%)
Support & Resistance Levels
Support Level
$1.55
Resistance Level
$1.87
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.30
Wall Street Target
$7.75
(+381.4%)
Revenue Growth (YoY)
60.9%
Share & Embed Analysis
Last updated: April 02, 2026 5:47 AM ET
Data refreshes hourly during market hours. Next update: 6:47 AM
Data refreshes hourly during market hours. Next update: 6:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 56 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 63 BUY |
